From WikiLectures

Chemical formula of lovastatin

Statins are competitive inhibitors of HMG-CoA reductase. HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase is an enzyme that catalyzes the major step in cholesterol synthesis, the conversion of HMG-CoA to mevalonic acid.

Its inhibition reduces intrahepatic cholesterol synthesis, which leads to an increase in the number of LDL-receptors on hepatocytes, increased uptake of LDL by the liver, and thus to a decrease in circulating blood cholesterol.

Another effect of statins is inhibition of smooth muscle cell proliferation in the vessel wall, improvement of endothelial cell function, stabilization of the atherosclerotic plaque, it also has antiplatelet and anti-inflammatory effects.

Pharmacokinetics[edit | edit source]

About 30 % of the administered dose is absorbed from the intestine, statins are taken up by the liver, where they are metabolized and then excreted by the bile.

Indications[edit | edit source]

The main indication for statin therapy is the treatment of hypercholesterolemia[1], as well as the achievement of target LDL cholesterol levels in high-risk patients with normal cholesterolemia. They are used in the treatment of familial hypercholesterolemia type IIa. With statin therapy, up to a 40 % reduction in LDL-cholesterol levels can be achieved (in combination with ion exchangers up to 60 %).

Contraindications[edit | edit source]

Pregnancy, lactation, childhood.

Side effects[edit | edit source]

Currently, there is a growing body of knowledge about the side effects of statins. It is likely that the frequency of already known side effects is higher than previously thought and that there are also previously unknown side effects. Previous studies have focused primarily on demonstrating a reduction in cardiovascular morbidity and overall mortality. However, they did not focus so much on identifying side effects. It should also be noted that many studies conducted in the past have ruled out up to 30% of patients in the pre-randomization phase due to comorbidities and concomitant medications!

According to some studies, statin treatment significantly reduces coenzyme Q10 (cholesterol is a precursor of CoQ10), which may be a factor in some of the side effects listed below (myopathy, rhabdomyolysis, neuropathy) – probably due to damage to membrane structure.

  • Increased activity of aminotransferases (regular checks) and creatine kinase;
  • myalgia;
  • severe skeletal muscle myopathy with pain, high creatine kinase activity and hyperkalemia; necessary interruption of therapy, otherwise the possibility of transition to rhabdomyolysis with myoglobinuria and renal failure - these conditions may rarely occur in monotherapy, the much higher incidence is reported in combination with CYP3A4 inhibitors (erythromycin, SSRI, azole antifungals, fibrates, cyclosporine);
  • polyneuropathy - predilection for HD (up to 10% of patients?);
  • tendinitis, tendon ruptures (t. Achillei, m. quadriceps, m. biceps femoris);
  • sleep disorders (up to 10 %?);
  • cataract;
  • CNS bleeding;
  • increased risk of DM.

Due to the above findings, some professional societies recommend substituting coenzyme Q10 in statin therapy. Especially with long-term therapy, in the event of an emergency or with an increased risk of cellular damage.

Representatives (by increasing lipid-lowering efficacy)[edit | edit source]

  • pravastatin tbl.10 a 20 mg,
  • lovastatin,
  • fluvastatin (ve formě s prodlouženým účinkem),
  • simvastatin tbl. 10–40 mg,
  • atorvastatin tbl. 10, 20 a 40 mg,
  • rosuvastatin tbl. 10, 20 a 40 mg.[1]

References[edit | edit source]

Related articles[edit | edit source]

References[edit | edit source]

  1. a b Incomplete citation of article.  HRADEC, Jaromír – BULTAS, Jan – ŽELÍZKO, Michael. Stabilní angina pectoris: Doporučený diagnostický a léčebný postup České kardiologické společnosti. 2010, vol. 52, no. 9, p. 543-560, ISSN 1803-7712. 

External links[edit | edit source]

Source[edit | edit source]

  • LINCOVÁ, Dagmar – FARGHALI, Hassan. Základní a aplikovaná farmakologie. 2. edition. Galén, 2007. 0 pp. ISBN 978-80-7262-373-0.